Current therapeutic strategies in connective tissue disease-related interstitial lung disease: introduction to the special issue

Abstract

This Editorial introduces the Special Issue on the efficacy and safety of current treatment strategies for patients with connective tissue disease-related interstitial lung disease, including the use of immunosuppressants, such as cyclophosphamide, mycophenolate mofetil and rituximab, and antifibrotic drugs.

Keywords

• connective tissue diseases
• cyclophosphamide
• interstitial lung diseases
• mycophenolate
• nintedanib
• pierfenidone
• rituximab